AQP4 and Encephalopathy: Overall, we recruited 58 subjects seropositive for MOG-IgG and seronegative for AQP4-IgG, including 23 (39.7%, 23/58) subjects with seizures and/or encephalopathy and 35 subjects without seizures or encephalopathy.